Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
DNA2 protein destruction dictates DNA hyperexcision, cGAS-STING activation, and innate immune response in CDK12-deregulated cancers.
Sun R et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12.
Troester S et al.
Nature Communications, 2025
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.
Ribeiro S et al.
Cancers, 2021
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Biswas R et al.
Cold Spring Harbor Molecular Case Studies, 2016
Structural and Functional Analysis of the Cdk13/Cyclin K Complex.
Greifenberg AK et al.
Cell Reports, 2016
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Ekumi KM et al.
Nucleic Acids Research, 2015
Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex.
Bartkowiak B et al.
The Journal of Biological Chemistry, 2015
Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM et al.
The Journal of Biological Chemistry, 2014
The structure and substrate specificity of human Cdk12/Cyclin K.
Bösken CA et al.
Nature Communications, 2014
Select a paper to view details